Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results
Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.
Why is Vera Therapeutics stock reversing its premarket gains?
Vera Therapeutics (VERA) shares ripped higher in premarket trading on September 15 as investors reacted to landmark clinical data. The biopharmaceutical firm announced that its lead therapy TRUTAKNA (atacicept-vymj) met all primary and secondary endpoints in the final 104-week efficacy analysis of its Phase 3 ORIGIN 3 trial for primary IgA nephropathy (IgAN).
Vera Stock Slides Despite Positive Phase 3 Results
Vera Therapeutics (NASDAQ:VERA) stock is down 2% to trade at $33.34, reversing earlier gains after disclosing positive late-stage ORIGIN 3 trial results for the company's TRUTAKNA drug.
Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy
Vera Therapeutics is upgraded to Buy following TRUTAKNA's FDA approval and encouraging eGFR data. The FDA's exploratory eGFR analysis shows stable kidney function with TRUTAKNA, supporting the bull case ahead of full phase 3 data in Q3 2026. TRUTAKNA faces competition from Otsuka's VOYXACT and Vertex's povetacicept but enjoys a commercial head start and broad label.
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
Vera Therapeutics NASDAQ: VERA said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease progression.
Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript
Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript
$20 Billion: Inside Nvidia's VERA CPU Bet to Break the Intel-AMD Duopoly
You can argue about almost every line in a NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) earnings release.
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision
Deerfield Management Company bought 418,538 Vera Therapeutics shares in the fourth quarter; the estimated trade size was $14.87 million. Meanwhile, the quarter-end position value rose by $99.77 million, reflecting both the new shares held and price appreciation.
Vera Therapeutics, Inc. (VERA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Vera Therapeutics, Inc. (VERA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Vera Therapeutics: Hold Rating Based On Potential For Atacicept In IgAN (Rating Downgrade)
Vera Therapeutics is downgraded from 'Strong Buy' to 'Hold' due to intensifying competition in the IgAN space. VERA's atacicept met the primary endpoint in the phase 3 ORIGIN trial, enabling a BLA submission and Priority Review with a PDUFA date of July 7, 2026. Competitive risks are heightened by Otsuka's VOYXACT, which shows superior proteinuria reduction and more convenient dosing.
Wall Street Analysts See a 53.05% Upside in Vera Therapeutics (VERA): Can the Stock Really Move This High?
The consensus price target hints at a 53.1% upside potential for Vera Therapeutics (VERA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
